PDC Therapeutics
PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies. They focus on proprietary Sagitta® biodegradable conjugation platforms that enhance therapeutic index, pharmacokinetics, and manufacturability. The company collaborates with multinational pharmaceutical companies and is supported by an industry-experienced board.
Industries
Nr. of Employees
small (1-50)
PDC Therapeutics
Lausanne Office, PDC Therapeutics SA, Route de la Corniche 2, 1066 Epalinges, Switzerland
Products
RS-0139
Tumor‑targeted docetaxel delivery candidate built on a biodegradable conjugation nanocarrier platform; advanced into Phase I dose‑escalation clinical study.
RS-0337
Preclinical oncology candidate targeting HER2 built on a biodegradable conjugation nanocarrier platform.
RS-0461
Preclinical oncology candidate targeting integrin, constructed using a biodegradable conjugation nanocarrier platform.
RS-0625
Preclinical oncology candidate targeting integrin using a biodegradable conjugation nanocarrier platform.
RS-0735
Preclinical oncology candidate (target undisclosed) using a biodegradable conjugation nanocarrier platform.
RS-0139
Tumor‑targeted docetaxel delivery candidate built on a biodegradable conjugation nanocarrier platform; advanced into Phase I dose‑escalation clinical study.
RS-0337
Preclinical oncology candidate targeting HER2 built on a biodegradable conjugation nanocarrier platform.
RS-0461
Preclinical oncology candidate targeting integrin, constructed using a biodegradable conjugation nanocarrier platform.
RS-0625
Preclinical oncology candidate targeting integrin using a biodegradable conjugation nanocarrier platform.
RS-0735
Preclinical oncology candidate (target undisclosed) using a biodegradable conjugation nanocarrier platform.
Services
Manufacture of clinical batches of lyophilized oncology drug products in a GMP‑certified facility; processes described as scalable and producing high‑purity material.
Collaborative development arrangements with multinational pharmaceutical companies to advance targeted nanomedicine candidates from preclinical into clinical development.
Design and execution capabilities for Phase I (dose‑escalation) clinical studies of oncology nanomedicine candidates.
Manufacture of clinical batches of lyophilized oncology drug products in a GMP‑certified facility; processes described as scalable and producing high‑purity material.
Collaborative development arrangements with multinational pharmaceutical companies to advance targeted nanomedicine candidates from preclinical into clinical development.
Design and execution capabilities for Phase I (dose‑escalation) clinical studies of oncology nanomedicine candidates.
Expertise Areas
- Targeted drug delivery
- Polymer–drug conjugate development
- Oncology drug development
- Nanomedicine formulation
Key Technologies
- Polymer–drug conjugates (PDC)
- Biodegradable conjugation platforms
- Nanocarrier formation responsive to hydration
- Dual‑drug loading
News & Updates
PDC Therapeutics, a biotech company developing targeted Polymer-Drug Conjugate technologies…
PDC Therapeutics SA has passed the first test of its novel nanocarrier technology…
Therapies With No Compromise
Therapies With No Compromise
Therapies With No Compromise
PDC Therapeutics, a biotech company developing targeted Polymer-Drug Conjugate technologies…
PDC Therapeutics SA has passed the first test of its novel nanocarrier technology…
Therapies With No Compromise
Therapies With No Compromise
Therapies With No Compromise